Metabolomics is the methodical scientific study of biochemical processes associated with the metabolome—which comprises the entire collection of metabolites in any biological entity. Metabolome changes occur as a result of modifications in the genome and proteome, and are, therefore, directly related to cellular phenotype. Thus, metabolomic analysis is capable of providing a snapshot of cellular physiology. Untargeted metabolomics is an impartial, all-inclusive approach for detecting as many metabolites as possible without a priori knowledge of their identity. Hence, it is a valuable exploratory tool capable of providing extensive chemical information for discovery and hypothesis-generation regarding biochemical processes. A history of metabolomics and advances in the field corresponding to improved analytical technologies are described in Chapter 1 of this dissertation. Additionally, Chapter 1 introduces the analytical workflows involved in untargeted metabolomics research to provide a foundation for Chapters 2 – 5. Part I of this dissertation which encompasses Chapters 2 – 3 describes the utilization of mass spectrometry (MS)-based untargeted metabolomic analysis to acquire new insight into cancer detection. There is a knowledge deficit regarding the biochemical processes of the origin and proliferative molecular mechanisms of many types of cancer which has also led to a shortage of sensitive and specific biomarkers. Chapter 2 describes the development of an in vitro diagnostic multivariate index assay (IVDMIA) for prostate cancer (PCa) prediction based on ultra performance liquid chromatography-mass spectrometry (UPLC-MS) metabolic profiling of blood serum samples from 64 PCa patients and 50 healthy individuals. A panel of 40 metabolic spectral features was found to be differential with 92.1% sensitivity, 94.3% specificity, and 93.0% accuracy. The performance of the IVDMIA was higher than the prevalent prostate-specific antigen blood test, thus, highlighting that a combination of multiple discriminant features yields higher predictive power for PCa detection than the univariate analysis of a single marker. Chapter 3 describes two approaches that were taken to investigate metabolic patterns for early detection of ovarian cancer (OC). First, Dicer-Pten double knockout (DKO) mice that phenocopy many of the features of metastatic high-grade serous carcinoma (HGSC) observed in women were studied. Using UPLC-MS, serum samples from 14 early-stage tumor DKO mice and 11 controls were analyzed. Iterative multivariate classification selected 18 metabolites that, when considered as a panel, yielded 100% accuracy, sensitivity, and specificity for early-stage HGSC detection. In the second approach, serum metabolic phenotypes of an early-stage OC pilot patient cohort were characterized. Serum samples were collected from 24 early-stage OC patients and 40 healthy women, and subsequently analyzed using UPLC-MS. Multivariate statistical analysis employing support vector machine learning methods and recursive feature elimination selected a panel of metabolites that differentiated between age-matched samples with 100% cross-validated accuracy, sensitivity, and specificity. This small pilot study demonstrated that metabolic phenotypes may be useful for detecting early-stage OC and, thus, supports conducting larger, more comprehensive studies. Many challenges exist in the field of untargeted metabolomics. Part II of this dissertation which encompasses Chapters 4 – 5 focuses on two specific challenges. While metabolomic data may be used to generate hypothesis concerning biological processes, determining causal relationships within metabolic networks with only metabolomic data is impractical. Proteins play major roles in these networks; therefore, pairing metabolomic information with that acquired from proteomics gives a more comprehensive snapshot of perturbations to metabolic pathways. Chapter 4 describes the integration of MS- and NMR-based metabolomics with proteomics analyses to investigate the role of chemically mediated ecological interactions between Karenia brevis and two diatom competitors, Asterionellopsis glacialis and Thalassiosira pseudonana. This integrated systems biology approach showed that K. brevis allelopathy distinctively perturbed the metabolisms of these two competitors. A. glacialis had a more robust metabolic response to K. brevis allelopathy which may be a result of its repeated exposure to K. brevis blooms in the Gulf of Mexico. However, K. brevis allelopathy disrupted energy metabolism and obstructed cellular protection mechanisms including altering cell membrane components, inhibiting osmoregulation, and increasing oxidative stress in T. pseudonana. This work represents the first instance of metabolites and proteins measured simultaneously to understand the effects of allelopathy or in fact any form of competition. Chromatography is traditionally coupled to MS for untargeted metabolomics studies. While coupling chromatography to MS greatly enhances metabolome analysis due to the orthogonality of the techniques, the lengthy analysis times pose challenges for large metabolomics studies. Consequently, there is still a need for developing higher throughput MS approaches. A rapid metabolic fingerprinting method that utilizes a new transmission mode direct analysis in real time (TM-DART) ambient sampling technique is presented in Chapter 5. The optimization of TM-DART parameters directly affecting metabolite desorption and ionization, such as sample position and ionizing gas desorption temperature, was critical in achieving high sensitivity and detecting a broad mass range of metabolites. In terms of reproducibility, TM-DART compared favorably with traditional probe mode DART analysis, with coefficients of variation as low as 16%. TM-DART MS proved to be a powerful analytical technique for rapid metabolome analysis of human blood sera and was adapted for exhaled breath condensate (EBC) analysis. To determine the feasibility of utilizing TM-DART for metabolomics investigations, TM-DART was interfaced with traveling wave ion mobility spectrometry (TWIMS) time-of-flight (TOF) MS for the analysis of EBC samples from cystic fibrosis patients and healthy controls. TM-DART-TWIMS-TOF MS was able to successfully detect cystic fibrosis in this small sample cohort, thereby, demonstrating it can be employed for probing metabolome changes. Finally, in Chapter 6, a perspective on the presented work is provided along with goals on which future studies may focus.

Les furocoumarines sont des phytoalexines offrant un potentiel thérapeutique important. Les travaux présentés ici portent sur les cytochromes P450 participant à leur voie de biosynthèse. Une étude «structure-fonction» de la cinnamate-4-hydroxylase (C4H) a été réalisée pour identifier les déterminants de la faible sensibilité de la C4H de Ruta graveolens (CYP73A32) au psoralène. Deux régions protéiques semblent impliquées dans l’inactivation différentielle entre CYP73A32 et CYP73A1. L’une, entre les résidus 31 et 58, est responsable de l’affinité pour le psoralène. L’autre, entre les résidus 229 et 379, contrôle la vitesse d’inactivation. La caractérisation de nouveaux P450 de la biosynthèse des furocoumarines a été entreprise. D’une part, plusieurs ADNc partiels ont été clonés chez Ruta graveolens. D’autre part, CYP71AJ1 isolé chez Ammi majus, a été caractérisé comme étant une psoralène synthase. La spécificité de CYP71AJ1 pour la marmésine a été approchée par l’étude d’un modèle 3D. Mots clés : cytochrome P450, psoralène synthase, cinnamate-4-Hydroxylase, C4H, métabolite secondaire, Ruta graveolens, Ammi majus, inactivation autocatalytique, furocoumarines, psoralène, (+)-marmésine, Modélisation 3D, (+)-columbianetine / Furocoumarins are phytoalexins known as efficient therapeutic agents. The work reported here focuses on cytochromes P450 involved in their biosynthesis pathway. A “structure-function” study was realized to understand how C4H from Ruta graveolens (CYP73A32) can resist to psoralen mechanism-based inactivation. Two parts of the protein seems involved in the differential susceptibility of CYP73A32 and CYP73A1 to psoralen. The first, between amino acids 31 and 58, defines differential affinity to psoralen. The second between residues 229 and 379 controls inactivation kinetic. The second part of this work was devoted to cloning and identification of new P450 involved in furocoumarin biosynthesis. On the one hand, several partial cDNA were cloned from Ruta graveolens. On the other hand, CYP71AJ1, cloned from Ammi majus, was identified as a psoralen synthase. The specificity of CYP71AJ1 for marmesin was approached by the study of a 3D model.

Les Stations de Traitement des Eaux Usées (STEU) sont l'une des principales sources de rejet de résidus médicamenteux dans l'environnement. Depuis 2009, les Zones de Rejet Végétalisées (ZRV) sont mises en oeuvre entre le rejet de la STEU et le milieu récepteur, mais leurs capacités d'abattement sont encore peu étudiées. Pour combler ce manque, les performances d'épuration de 2 STEU et de leur ZRV, ont été évaluées pendant 2 années. Les résidus médicamenteux (86) ont eu une majorité de rendements d'épuration compris entre 30 et 70 % dans les ZRV et avec des maximums en été et des minimums en hiver. Relativement aux abattements observés sur les STEU en amont, la contribution des ZRV à l'épuration globale du site était inférieure à 30 % du flux entrant. Aussi, la réduction des volumes d'eau rejetés au milieu naturel a été corrélée avec une augmentation des concentrations en résidus médicamenteux. Par ailleurs, les plantes ont montré une capacité d'absorption des médicaments spécifique à l'espèce étudiée, alors que l'observation des concentrations dans les boues, a mis en évidence une tendance à une adsorption en été et un relargage en hiver des micro-polluants. / Wastewater Treatment Plants (WWTP) are considered as one of the most important pharmaceutical compound discharges into the environment. Since 2009, French Water Agencies, promote Surface Flow Treatment Wetlands (SFTWs) at the outlet of WWTPs, between the WWTP and the receiving aquatic environment but their removal efficiencies are not well investigated. To overcome these lacks of knowledge, pollutant removal efficiencies of 2 WWTP and their SFTW were monitoring during 2 years. ln regard to pharmaceutical compounds (86), SFTW removal efficiency rates ranged from 30 to 70% with maximum values in summer and minimum values in winter. The SFTW removal efficiency contributions to WWTP were inferior to 30%. ln addition, SFTW inflow reductions were correlated with an increase of drug compound concentrations in the outflow. Furthermore, there was a specific absorption of these micro pollutants by plants whereas there were dynamic interactions between sampled mud and drugs residues with an adsorption during summer and a release during winter.

The fate and behaviour of estrogens in the environment are of concern due to the compounds’ endocrine disruption potential. Estrogens, namely 17β-estradiol (E2), estrone (E1), and estrogen sulphates, i.e. 17β-estradiol-3-sulphate (E2-3S) and estrone-3-sulphate (E1-3S) excreted by livestock constitute a potential source for estrogen contamination in the environment. A method was developed to separate and quantify the hormones by high-performance-liquid-chromatography (HPLC) and ultraviolet detection (UV). A combination of dichloromethane (DCM) and dicyclohexylamine hydrochloride (DCH·HCl) gave recoveries from 97.3 to 107% for E1-3S extraction from aqueous solutions. The recoveries from soil samples ranged from 80.9 to 95.2% (E2-3S), and from 86.3 to 91.7% (E1-3S), respectively. Results of batch sorption studies showed that Freundlich isotherms were nonlinear (N ≠ 1) with Kf values ranging from 34.2 to 57.2, and from 3.42 to 4.18 mg¹-N LN kg⁻¹ for E1, and E1-3S, respectively, indicating the sorption affinity of E1-3S was about an order of magnitude lower than that of E1. The hydrophilic sulphate group of E1-3S possibly shielded the compound from hydrophobic interactions with the soil organic matter and allophanic clay minerals that were proposed as sorbents for E1. Contraction of clay minerals, “salting out” and competitive sorption of artificial urine constituents were likely to have been responsible for observed changes in Freundlich parameters when artificial urine was used as mediator matrix. Plotting the effective distribution coefficient as a function of hypothetical exposure concentrations facilitated the comparison of the sorption behaviour of both compounds as influenced by the mediator solution. The results emphasized that using the CaCl₂ matrix might result in false inferences for the sorption behaviour of these compounds in a dairying environment. The four hormones rapidly degraded in the agricultural soils under aerobic conditions, and the majority of the compounds degraded > 50% within the first 24 hrs. Soil arylsulphatase activities were directly correlated with degradation rate constants of the estrogen sulphates. Estrone was identified as a metabolite of E2 and E1-3S, and these three compounds were observed as metabolites of E2-3S. Single-first order (SFO) and double first-order in parallel (DFOP) kinetics were used to model the degradation and metabolite formation data. The results showed that the DFOP model was in most cases better able to predict the parent compound degradation than the SFO model, and also enabled to estimate accurate degradation endpoints. ER-CALUX® analysis revealed the formation of estrogenicity during E2-3S degradation, which could partly be explained by the formation of the metabolites E2 and E1. Transport studies with E1-3S and E1 showed that the transport and retention of both compounds were significantly influenced by the mediator matrix. While no breakthrough curves (BTCs) were recorded during hormone application in CaCl₂ (10 mM) both hormones were detected in the leachate when applied in artificial urine. Rate-limited sorption processes were proposed for the delayed arrival of the hormone BTCs compared with a conservative bromide tracer. Intense colouration of the leachate during the artificial urine experiments suggested the hormones were likely to be moved by colloid-facilitated transport. Furthermore, the detection of residue hormone and metabolite concentrations implied that degradation of E1-3S and E1 was hampered by urine constituents such as glycine and urea.

Polyketide products are useful compounds to research and industry but can be difficult to access due to their richness in stereogenic centers. Type I polyketide synthases offer unique engineering opportunities to access natural stereocontrol and resultant complex compounds. The development of a controlled in vitro platform based around type I polyketide synthases is described. It has been used to produce a small library of polyketide fragments on an unprecedented and synthetically-relevant scale and explore polyketide synthase enzymology. / text

Le nombre croissant d'admissions hospitaliairres provoquées par les effets second d'un traitement thérapeutique constitue un problème majeur de santé publique. L'hépatite médicamenteuse, la pathologie iatrogène la plus fréquente pose également un problème d'ordre économique. En effet, l'hépatotoxicité des médicaments constitue la première cause de leur retrait du marché pharmaceutique. La non détection de ce potentiel hépatotoxique, avant commercialisation provient essentiellement du caractère idiosyncratique de ce type d'hépatites médicamenteuscs. Cclles-ci se divisent en deux types : les hépatites médicamenteuses qualifiées de directes et à l'inverse les hépatites médicamenteuses immunoallergiques. Les mécanismes sous-jacents des hépatites médicamenteuses idiosyncratiques sont généralement méconnus et leur comprehension constitue donc à la fois un impératif de santé publique et économique. Mon travail s'est inscrit dans cette optique et a consisté à appréhendcr les premières étapes impliquées dans l'apparition des, hépatites idiosyncratiques et en particulier celle induite par l'acide tiénilique (AT). En effet, ce diurétique, retiré du marché pharmaceutique français en 1992 a été responsable de nombreuses hépatites imrnunoallergiques., Les patients atteints de ces hepatitis induites par l'AT possèdent des anticorps très spécifiques, désignés anti-LKM2, dirigés contre le CYP2C9, le P450 responsible de la métabolisation de l'AT. Les principaux resultants obtenus sont les suivants : nous avons montré que l'activation de l'isomère de l'acide tiénilique par les microsomes hépatiques humains conduit à la formation de sulfoxydes de thiophène. Ces metabolites électrophiles instables, comme ceux de l'AT, réagissent avec les proteins hépatiques avec lesquelles ils forment des adduits covalents. La formation de sulfoxydes de thiophène liée à l'activation de l'AT chez l'homme constitue probablement la première étape impliquée dans les hepatites induites par ce médicament. Nous avons ensuite démontré que la fixation covalente de l'AT après activation par les microsomes hépatiques est très spécifique chez l'homme. En effet le CYP2C9 est la cible principale des metabolites de l'AT. L'alkylation du CYP2C9 par l'AT in vivo chez l'homme pourrait constituer la seconde étape impliquée dans l'hépatite induite par ce medicament. Nous avons ensuite montré que le CYP2C11, l'homologue du CYP2C9 humain, est une cible privilégiée des métabolites de l'AT chez le rat. Nous montrons que cette fixation covalente sur le CYP2C11 est observable à la fois in vitro et in vivo. Nous montrons que les adduits de l'AT chez le rat sont principalement localizes au niveau des hépatocyte centrolobulaires. L'alkylation majoritaire des hépatocytes centrolobulaires chez l'homme pourrait favoriser la présentation d'adduits d'AT aux cellules immunocompétentes sanguines et constituer la troisième étape des hepatitis autoimmunes induites par le medicament. Nous montrons qu'en effet les patients traits avec l'AT possèdent des anticorps capables de reconnaitre l'AT lorsqu'il est lié à des proteins.

Made available in DSpace on 2014-07-29T15:29:08Z (GMT). No. of bitstreams: 1 Marcelo de sousa Vieira.pdf: 1862129 bytes, checksum: 7cc8be40ceb11c75c5ec56b362ffec29 (MD5) Previous issue date: 2009-04-14 / The animal replacement in expirements has been very encouraged by government and other institutions. However, in drugs development the animal replacement is not yet a reality, like at oral acute systemic tests. The validation of in vitro protocols is necessary for data generation with reproducibility, repetability and accuracy. In this study was validated at the Laboratório de Farmacologia e Toxicologia Celular- Faculdade de Farmácia/Universidade Federal de Goiás the protocol already validated by three laboratories (two in the USA and one at United Kingdom) and coordinated by ICCVAM: In Vitro Cytotoxicity Methods for Estimating Starting Doses for Acute Systemic Toxicity Tests, using the neutral red uptake in BAL/c 3T3-A31 cell line. It was used the grandisine, a lignan, and its major metabolite taken by fungi biodegradation. Our research group has identified a potential anti-tumoral action of grandisine, data not yet published. After in house validation we estimated the LD50 of grandisin and 4-O-demethylgrandisin: 617.72 mg/kg and 429.95 mg/kg, respectively. Both were classified under the GSH category 4. / A substituição ou redução do uso de animais em experimentos para a avaliação de toxicidade tem sido bastante encorajada e tem recebido grandes incentivos, inclusive financeiros, governamentais e institucionais. No entanto, a substituição completa da maioria dos testes mandatórios por agências reguladoras do setor ainda não é realidade, a exemplo, o teste de toxicidade oral aguda sistêmica. Neste contexto, se aplica a validação de testes in vitro para estimar dados in vivo. No presente trabalho, realizamos a validação in house do protocolo internacional e multilaboratorial recomendado pelo Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): Utilização da Citotoxicidade In Vitro na Estimativa de Doses Iniciais para Testes de Toxicidade Oral Aguda Sistêmica. Para tal, utilizamos o método de captação do corante vermelho neutro e a linhagem celular fibroblástica de camundongos BALB/c 3T3-A31. Dentre as substâncias recomendadas pelo ICCVAM para a validação do método foram investigadas 9 substâncias. A metabolização de produtos pelo organismo vivo é uma grande limitação dos testes in vitro. Utilizamos a grandisina, um tipo de ligana com grande potencial antitumoral e seu metabólito majoritário como substâncias modelos. Com utilização do metabólito conseguimos transpor esta barreira dos testes in vitro. Os resultados demonstraram que os dados obtidos estão em consonância com os dados da literatura sendo possível classificar ambas as substâncias na categoria GHS 4: grandisina e 4-Odemetilgrandisina: 617,72 mg/kg and 429,95 mg/kg, respectivamente.

P-glycoprotein (P-gp) protects the mammalian intestinal epithelium by effluxing toxins from the epithelial cells as well as release of human endocannabinoids that inhibit neutrophil infiltration. Diminished or dysfunctional P-gp is associated with intestinal inflammation including ulcerative colitis (UC). Due to the microbiome dysbiosis associated with UC, we hypothesize that the healthy microbiota promote colonic P-gp expression. Utilizing mouse models of antibiotic treatment, microbiota reconstitution, and metabolite perturbation, we have shown butyrate and secondary bile acids, dependent on vancomycin-sensitive bacteria, induce P-gp expression in vivo. We have shown these metabolites together potentiate induction of P-gp in intestinal epithelial cell lines in vitro, which is sufficient to inhibit primary human neutrophil transmigration. Furthermore, in UC patients we find diminished P-gp expression is coupled to reduction of anti-inflammatory endocannabinoids and luminal content with reduced capability to induce P-gp expression. Additionally, we have found butyrate contributes to P-gp expression via histone deacetylase inhibition, and secondary bile acids regulate P-gp expression via nuclear receptors pregnane X receptor and vitamin D receptor. Employing RNA sequencing (RNAseq) in IECs uncovered signaling networks that are uniquely triggered with the combination of butyrate and secondary bile acids, suggesting additional pathways required for maximal P-gp expression in the colon. Together we identify a mechanistic link between cooperative functional outputs of the complex microbial community and suppression of intestinal inflammation. These data emphasize the importance of the intestinal microbiome in driving the P-gp axis to suppress aberrant neutrophil infiltration and identify potential therapeutic targets for promoting P-gp expression in an inflamed colon to reset homeostasis.

Schilddrüsenhormone (TH) regulieren Metabolismus und Energiestoffwechsel. Der TH‐Metabolit (THM) 3,5‐T2 (3,5‐Diiod‐L‐Thyronin) aktiviert Fett‐Oxidation und mitochondriale Atmung. Der THM 3‐Iodothyronamin (3‐T1AM) beeinflusst zusätzlich glukoregulatorische Prozesse. THM können zur Reduktion von Körperfett beitragen. Um 3,5‐T2 im humanen Serum nachzuweisen sollte ein Immunoassay aufgebaut, validiert und angewendet werden. In intakten hepatozellulären (HepG2) sowie pankreatischen ß‐Zellen (MIN6) sollte untersucht werden ob THM durch Modulation der mitochondrialen Aktivität die zelluläre Substratverstoffwechslung (3,5‐T2) und Insulinsekretion (3‐T1AM) regulieren können. Der Immunoassay ist sensitiv, spezifisch und misst zuverlässig 3,5‐T2 im humanen Serum. Hyper‐ und Hypothyreose zeigen vergleichbare 3,5‐T2 Konzentrationen, jedoch akkumuliert 3,5‐T2 bei sekundären Erkrankungen der Schilddrüse und athyreoten Patienten unter Thyroxin‐Supplementation. In HepG2‐Zellen konnte die Aktivierung der mitochondrialen Atmung durch 3,3‘,5‐Triiod‐L‐Thyronin (T3), jedoch nicht durch 3,5‐T2 stimuliert werden. Die Expression von TH‐transporters (THT) war gering verglichen mit Maus‐Hepatozyten. MIN6 exprimiert THT vergleichbar mit Langerhansschen Inselzellen der Maus. 3‐T1AM wird in die Zelle aufgenommen, zu 3‐Iodothyroessigsäure (TA1) metabolisiert, und wieder exportiert. Nach 3‐T1AM Gabe ist die mitochondriale ATP‐Produktion sowie die Glukose‐stimulierte Insulinsekretion (GSIS) vermindert. 3,5‐T2 zirkuliert in euthyreoten Individuen, ist nicht an der zentralen Regulation der TH‐Achse beteiligt, wird extrathyroidal gebildet und niedrige T3‐Werte können durch erhöhtes 3,5‐T2 erklärt werden. HepG2 erwies sich als ungeeignetes Zellmodell, da wenige THT vorhanden sind, 3,5‐T2 die Plasmamembran wahrscheinlich nicht passieren kann und damit die Aktivierung der Mitochondrien aus bleibt. In MIN6 wurde gezeigt, dass die GSIS nicht ausschließlich an der Plasmamembran durch 3‐T1AM reguliert wird. / Thyroid hormones (TH) regulate metabolism and energy metabolism. The TH‐metabolite (THM) 3,5‐T2 (3,5‐diiodo‐L‐thyronine) activates fat oxidation and mitochondrial respiration. The THM 3‐T1AM (3‐iodothyronamine) influences in addition glucoregulatory processes. THM may support reduction in body fat mass. It was the idea to establish, validate and apply an immunoassay to determine 3,5‐T2 in human serum. Using intact hepatocellular (HepG2) as well as pancreatic ß‐cells (MIN6) it should be tested if THM can modulate mitochondrial activity, resulting in increased cellular substrate usage (3,5‐T2) as well as decreased insulin secreation (3‐T1AM). The established immunoassay is sensitive, specific and detects precisely 3,5‐T2 in human serum. Hyper‐ and hypothyroidism shows similar 3,5‐T2 concentrations, although 3,5‐T2 accumulates in secondary thyroidal illness as well as in athyreotic patients under thyroxine‐supplementation. Using HepG2 cells, mitochondrial respiration was stimulated by 3,3‘,5‐triiodo‐L‐thyronine (T3), but 3,5‐T2 had no effect. Expression of TH‐transporters (THT) was low compared to murine hepatocytes. In contrast, MIN6 express THT comparable to murine Langerhans islets. 3‐T1AM is taken up by the cell, metabolized to 3‐iodothyroacetic acid (TA1) and following export. After 3‐T1AM application mitochondrial ATP‐production as well as glucose‐stimulated insulin secretion (GSIS) was reduced. 3,5‐T2 circulates in euthyroid individuals, is not involved in central regulation of TH‐axis, is produced extrathyroidally and low T3 values can be explained by increased 3,5‐T2. HepG2 was shown to be an inappropriate cellmodel, because THT are merely expressed, suggesting that 3,5‐T2 is not able to pass the plasma membrane, thereby preventing mitochondrial activation. In addition, it was shown in MIN6 cells, that GSIS is not exclusively regulated at the plasma membrane level via 3‐T1AM.

The aim of this project has been to investigate whether there are correlations to be found between gut microbes and serum metabolites, which could be involved in the development of epilepsy. To do so, metabolomics data containing metabolites and metagenomics data containing bacteria have been integrated and used in a pipeline utilizing the software package DIABLO in R Studio. DIABLO stands for Data Integration Analysis for Biomarker discovery using Latent cOmponents and utilizes multi-block pls-da to integrate multiple omics data sets to find potential biomarkers. The results in this project are mainly divided into two groups, the first group being from taking samples at an early time point, where subjects have not yet developed symptoms of epilepsy and the second group being from taking samples at a late time point, where the subjects have developed epilepsy. To find biomarkers in the data used for the integration, two subgroups are of highest interest, namely subgroup PTE, which is the group that develops epilepsy symptoms after an induced trauma to the brain, as well as subgroup TBI which do not develop epilepsy symptoms after an induced trauma to the brain. Results from the early time point suggests that bacteria such as those from Phelethenecus, Christenselellales, Ventrimonas, Ruminococcaceae and Acetatifactor, as well as metabolites such as LPC 17:0, Indole and Indole-3-carboxyaldehyde might be of interest in finding biomarkers previous to the development of epilepsy after induced brain trauma.  Results from the late time point suggests that bacteria such as those from Muribaculaceae and Avidehalobacter, as well as metabolites such as Dioctyl sulfosuccinate, Canrenone, LPC 18:0, Uric acid, Arjunolic acid and Pseudouridine might be of interest in finding underlying mechanisms behind the existing condition of epilepsy. The hope is that findings in this paper might aid in future development of knowledge behind this disease as well as its underlying mechanisms.